Biotechnology stocks had a great run over the past few years but likely got ahead of themselves early this year. The current mean-reversion move to the downside in biotechnology stocks looks feels heavier and looks to have more to go. Here is how I am measuring the downside targets.

Serge Berger
http://thesteadytrader.com

Pin It on Pinterest

Share This

GET OUR FREE DAILY TRADING VIDEOS

Delivered to your inbox!

You should get your first video tomorrow!